Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Janfar-F is a branded generic combination medication developed by Janjaes Pharmaceutical, primarily indicated for the management of Polycystic Ovary Syndrome (PCOS) and associated female infertility. The formulation typically consists of a combination of myo-inositol and d-chiro-inositol, which act as insulin-sensitizing agents to improve metabolic parameters, reduce androgen levels, and restore regular ovulatory cycles. Additionally, it contains l-methylfolate (the active form of folic acid) to support reproductive health and prevent neural tube defects, and cholecalciferol (Vitamin D3) to address common deficiencies that can exacerbate PCOS symptoms. By targeting the underlying insulin resistance and hormonal imbalances, Janfar-F aims to improve oocyte quality and increase pregnancy rates in women with PCOS.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Janfar-F.